# A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

> **NCT01691755** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 196 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** aleglitazar

## Key facts

- **NCT ID:** NCT01691755
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691755, "A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01691755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*